Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

16:08
10/09/16
10/09
16:08
10/09/16
16:08

Merck reports 18-month data from KEYNOTE-010, other Keytruda data sets

Merck announced that Keytruda demonstrated superiority in overall survival at 18 months compared to standard of care chemotherapy -- docetaxel -- in patients with metastatic non-small cell lung cancer previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1, as well as patients with high levels of PD-L1 expression. The data, from the phase 2/3 KEYNOTE-010 trial, will be presented at the ESMO 2016 Congress. In addition, an analysis of patient-reported health-related quality of life outcomes showed more patients treated with Keytruda reported positive outcomes compared to patients treated with chemotherapy. Separately, researchers also presented an analysis of PD-L1 prevalence across three separate studies, including KEYNOTE-010. Overall, 66 percent of patients with metastatic NSCLC expressed any level of PD-L1, and 28 percent expressed high levels of PD-L1. Specifically, the new data from KEYNOTE-010 included six months of additional follow-up, with a median follow-up of 19.2 months, and showed superior outcomes of OS, PFS, and ORR with Keytruda compared to docetaxel in patients with PD-L1 expression as well as high levels of PD-L1 expression -- with consistency of outcomes across Keytruda doses. In patients with PD-L1 expression, OS at 18 months was 37 percent with Keytruda 2 mg/kg, 43 percent with Keytruda 10 mg/kg, and 24 percent with docetaxel. Among all patients, median OS was 10.5 months with Keytruda 2 mg/kg, 13.6 months with Keytruda 10 mg/kg, and 8.6 months with docetaxel. ORR was 19 percent with Keytruda 2 mg/kg, 20 percent with Keytruda 10 mg/kg and 10 percent with docetaxel. Responses to Keytruda continued to be durable; among patients with any level of PD-L1 expression who responded to treatment, 60 percent on each of the Keytruda treatment arms were alive, progression-free, and had not received additional therapy for their disease, compared to 15 percent in the docetaxel treatment arm. In patients with high levels of PD-L1 expression, OS at 18 months was 46 percent with Keytruda 2 mg/kg, 52 percent with Keytruda 10 mg/kg, and 24 percent with docetaxel. In this group, median OS was 15.8 months with Keytruda 2 mg/kg, 18.8 months with Keytruda 10 mg/kg, and 8.2 months with docetaxel. ORR was 29 percent with Keytruda 2 mg/kg, 32 percent with Keytruda 10 mg/kg, and nine percent with docetaxel. Responses to Keytruda continued to be durable; among patients with high levels of PD-L1 expression who responded to treatment, 68 and 63 percent on the Keytruda 2 mg/kg and 10 mg/kg treatment arms, respectively, were alive, progression-free, and had not received additional therapy for their disease, compared to 15 percent in the docetaxel treatment arm. Treatment-related adverse events remained lower with Keytruda compared to docetaxel. Also reported at the ESMO 2016 Congress were health-related quality of life outcomes from the KEYNOTE-010 trial. Overall, from baseline to the 12-week assessment, patients treated with Keytruda reported numeric improvements, some of which were significant, in HRQoL and prolonged time to deterioration of lung cancer symptoms compared with docetaxel. Additionally, results from a third NSCLC abstract at the ESMO 2016 Congress explored, for the first time, the prevalence of PD-L1 in patients screened across multiple studies. The analysis assessed 4,784 patients with NSCLC who had tumors evaluable for PD-L1 expression and were screened for eligibility in three registrational studies of Keytruda -- KEYNOTE-001, KEYNOTE-010, and KEYNOTE-024. Based on this pooled analysis, 66 percent of patients across all three trials were determined to express PD-L1 and 28 percent were determined to have high levels of PD-L1 expression. These findings were similar across demographic and disease characteristics examined, including prior lines of therapy, age, tumor source, and histology.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

02:40
12/09/16
12/09
02:40
12/09/16
02:40
General news
FX Update: The euro eked out a fresh low »

FX Update: The euro eked…

ACTS

Actions Semiconductor

01:00
12/09/16
12/09
01:00
12/09/16
01:00
Conference/Events
Actions Semiconductor to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MTN

Vail Resorts

$160.92

-1.81 (-1.11%)

20:25
12/08/16
12/08
20:25
12/08/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MON

Monsanto

$104.70

-0.71 (-0.67%)

20:17
12/08/16
12/08
20:17
12/08/16
20:17
Hot Stocks
Washington sues Monsanto over PCB contamination »

Washington Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 27

    Jan

USAC

USA Compression

$18.01

-0.14 (-0.77%)

20:15
12/08/16
12/08
20:15
12/08/16
20:15
Syndicate
USA Compression 4.5M share Spot Secondary priced at $16.25 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ICHR

Ichor Holdings

20:11
12/08/16
12/08
20:11
12/08/16
20:11
Syndicate
Ichor Holdings 5.9M share IPO priced at $9.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:53
12/08/16
12/08
19:53
12/08/16
19:53
Periodicals
YouTube-NMPA settlement estimated at over $40M, NY Times says »

The agreement between…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:46
12/08/16
12/08
19:46
12/08/16
19:46
Hot Stocks
YouTube reaches agreement to pay out unclaimed song royalties »

The National Music…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

ATH

Athene Holding

19:33
12/08/16
12/08
19:33
12/08/16
19:33
Syndicate
Athene Holding 27M share IPO priced at $40.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MMM

3M

$175.88

-0.17 (-0.10%)

19:29
12/08/16
12/08
19:29
12/08/16
19:29
Hot Stocks
3M to sell identity management business to Gemalto for $850M »

3M announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SMI

SMIC

$5.99

-0.54 (-8.27%)

19:24
12/08/16
12/08
19:24
12/08/16
19:24
Hot Stocks
SMIC announces 10-for-1 reverse stock split »

Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$62.61

0.41 (0.66%)

19:10
12/08/16
12/08
19:10
12/08/16
19:10
Hot Stocks
Ventas raises quarterly dividend 6% to 77.5c per share »

Ventas said that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:08
12/08/16
12/08
19:08
12/08/16
19:08
Periodicals
Wells Fargo chairman appointed to sales investigation committee, Reuters says »

Wells Fargo chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:03
12/08/16
12/08
19:03
12/08/16
19:03
Periodicals
Former Wells Fargo managers file suit over fake accounts, Bloomberg reports »

Three former Wells Fargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

EIX

Edison International

$69.44

-0.17 (-0.24%)

18:42
12/08/16
12/08
18:42
12/08/16
18:42
Hot Stocks
Edison International raises annual dividend 13% to $2.17 per share »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLM

PolyMet Mining

$0.87

0.0001 (0.01%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Earnings
Breaking Earnings news story on PolyMet Mining »

PolyMet Mining reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$18.38

0.18 (0.99%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Hot Stocks
Match Group launches 'Swipe Ventures,' says Tinder CEO to step down »

Match Group's Tinder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

18:18
12/08/16
12/08
18:18
12/08/16
18:18
Hot Stocks
Biogen to present aducanumab Phase 1b data at CTAD meeting »

Biogen announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

HIVE

Aerohive

$5.41

0.18 (3.44%)

18:17
12/08/16
12/08
18:17
12/08/16
18:17
Hot Stocks
Discovery Group reports 9.1% stake in Aerohive Networks, sends letter to board »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

, ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

18:05
12/08/16
12/08
18:05
12/08/16
18:05
Periodicals
Outrigger Energy nears sale to midstream services provider, Forbes says »

Private-equity backed…

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

TRGP

Targa Resources

$54.20

0.38 (0.71%)

ETP

Energy Transfer Partners

$35.13

0.55 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$78.65

0.96 (1.24%)

18:02
12/08/16
12/08
18:02
12/08/16
18:02
Hot Stocks
Post Holdings settles egg antitrust class action claims »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENZN

Enzon

$0.44

-0.0027 (-0.62%)

17:54
12/08/16
12/08
17:54
12/08/16
17:54
Hot Stocks
Icahn says enters standstill pact with Enzon »

In an amended filing on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$52.27

0.15 (0.29%)

17:53
12/08/16
12/08
17:53
12/08/16
17:53
Hot Stocks
Leidos awarded $350M government contract »

Leidos, Reston, Virginia,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:50
12/08/16
12/08
17:50
12/08/16
17:50
Hot Stocks
Dominion Diamond sees FY17 production at Ekati diamond mine 4.5M carats »

Sees FY17 Ekati diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FNSR

Finisar

$34.13

1.89 (5.86%)

, AVGO

Broadcom

$170.71

2.16 (1.28%)

17:49
12/08/16
12/08
17:49
12/08/16
17:49
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

FNSR

Finisar

$34.13

1.89 (5.86%)

AVGO

Broadcom

$170.71

2.16 (1.28%)

GLPG

Galapagos NV

$58.95

0.71 (1.22%)

XTLY

Xactly

$14.35

0.35 (2.50%)

RH

Restoration Hardware

$38.99

1.05 (2.77%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

NCS

NCI Building

$17.85

0.6 (3.48%)

FRED

Fred's

$10.84

0.15 (1.40%)

USAC

USA Compression

$18.01

-0.14 (-0.77%)

FRO

Frontline

$7.71

0.37 (5.04%)

WSM

Williams-Sonoma

$56.90

0.61 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 14

    Dec

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.